Market Overview

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results
Related IBB
The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs
The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut
Related TTPH
40 Stocks Moving In Thursday's Mid-Day Session
Benzinga's Top Upgrades, Downgrades For September 6, 2018
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZN, RMTI, ... (GuruFocus)

Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) gained about 1.5 percent.

The following catalytic biotech events are set to occur this week:  


  • 2018 European Society of Cardiology Congress: Aug. 25-29 in Munich, Germany
  • 13th European Congress on Epileptology: Aug. 26-30 in Vienna, Austria
  • International Conference on Molecular Biology and Medicine: Aug. 27-28 in Dubai, UAE
  • 8th Global Experts Meeting on Advances in Neurology and Neuropsychiatry: Aug. 27-28 in Tokyo, Japan
  • 5th International Conference on Glycobiology & Glycoproteomics: Aug. 27-28 in Toronto, Canada
  • 21st World Congress on Radiology & Cancer Research: Aug 27-28 in Toronto
  • 14th International Conference on Clinical Gastroenterology and Hepatology: Aug. 29-30 in Toronto
  • 5th International Conference on Neglected Tropical & Infectious Diseases: Aug. 29-30 in Boston
  • 5th Annual Congress on Rare Diseases and Orphan Drugs: Aug. 29-30 in Boston
  • 4th Annual Congress on Infectious Diseases: Aug. 29-30 in Boston
  • 4th World Congress on Parkinsons & Huntington Disease: Aug. 29-30 in Zurich, Switzerland
  • 4th International Conference on Epilepsy & Treatment: Aug. 29-30 in Zurich
  • 32nd Annual World Dentistry Summit: Aug. 31-Sept. 1 in Boston
  • 6th World Summit on Heart, Stroke & Neurological Disorders: Aug. 31-Sept. 1 in Boston
  • 14th World Summit on Alzheimer's Disease, Dementia Care Research and Awareness: Aug. 31-Sept. 1 in Boston



Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) awaits FDA decision on Eravacycline, a fully synthetic fluorocycline being developed for complicated intra-abdominal infections.


The FDA is set to rule on Akcea Therapeutics Inc (NASDAQ: AKCA)'s NDA for Volanesorsen, a RNAi drug to treat patients with familial chylomicronemia syndrome. Akcea is a unit of Ionis Pharmaceuticals Inc (NASDAQ: IONS).

Clinical Trial Results

Pfizer Inc. (NYSE: PFE) will present late-phase data for Tafamidis, a TTR amyloid cardiomyopathy medication, at the European Society of Cardiology Congress on Monday.

Esperion Therapeutics Inc (NASDAQ: ESPR) is due to release Phase 3 data for bempedoic acid/ezetimibe, being evaluated for hypercholesterolemia.

Xenon Pharmaceuticals Inc (NASDAQ: XENE) is due to present Phase 1 data for its epilepsy treatment candidate XEN101 at the European Congress on Epileptology.

TG Therapeutics Inc common stock (NASDAQ: TGTX) has scheduled the release of Phase 3 UNITY-CLL study's top-line data for its TG-1101 and TGR-1202 combo to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma for the end of summer 2018.

Related Links:

Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates

Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug

Posted-In: Biotech Earnings News Previews FDA Top Stories Trading Ideas Best of Benzinga


Related Articles (ESPR + AKCA)

View Comments and Join the Discussion!

How The 'Real Economy' Has Fared During The Longest Bull Market In History

Barron's Picks And Pans: Electronic Arts, GlaxoSmithKline, Microsoft, Tesla And More